Jiangsu Hengrui Herombopag Olamine Tablets Technical Review Report (CXHS2000014-15)

Herombopag Olamine Tablets are a novel oral small molecule thrombopoietin receptor agonist indicated for the treatment of adult patients with severe aplastic anemia (SAA) who have had an inadequate response to immunosuppressive therapy (IST).


Jiangsu Hengrui Herombopag Olamine Tablets Technical Review Report (CXHS2000014-15) - cover page
Brand
Jiangsu Hengrui
Category
Drugs
Document type
Other
Language
Chinese
Pages
22
File format
PDF
File size
978 KB
Published
17 November, 2023
Updated
17 November, 2023
MD5 checksum
4EC88F92DC7B6DE61A0E0449C8211B85

About this manual

This document is a technical review report for the marketing authorization of Herombopag Olamine Tablets (海曲泊帕乙醇胺片) by Jiangsu Hengrui Medicine Co., Ltd. The drug is a small molecule TPO-R agonist intended for the treatment of adult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy. The review was conducted by the Center for Drug Evaluation of China's National Medical Products Administration.

The report covers basic information about the applicant and drug, verification and compliance evaluation, and comprehensive review opinions on pharmacology, clinical pharmacology, efficacy, safety, and risk-benefit assessment. The application received conditional approval and priority review status, with final processing opinions including technical conclusions and post-marketing requirements. This manual is written in Chinese.

What's inside

  • Basic Information
  • Verification and Compliance Evaluation
  • Indication
  • Pharmacological Evaluation
  • Clinical Pharmacology Evaluation
  • Efficacy Evaluation
  • Safety Evaluation
  • Risk Analysis and Control
  • Benefit-Risk Assessment
  • Processing Opinion

Specifications

Specifications2.5 mg, 3.75 mg, 5 mg (calculated as C25H22N4O5)
IndicationAdult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy (IST)
Recommended initial dosage7.5 mg once daily
Maximum dosage15 mg once daily
Chemical name(Z)-5-(2-羟基-3-(2-(3-甲基-5-氧代-1-(5,6,7,8-四氢萘-2-基)-1H-吡唑-4(5H)-亚基)肼基)苯基)呋喃-2-羧酸乙醇胺盐(1∶2)
Molecular formulaC25H22N4O5•2C2H7NO
Molecular weight580.64

Frequently asked questions

What is the indication of Herombopag Olamine Tablets?

It is indicated for adult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy (IST).

What are the available specifications of Herombopag Olamine Tablets?

The tablets are available in 2.5 mg, 3.75 mg, and 5 mg strengths (calculated as C25H22N4O5).

What is the recommended initial dosage for Herombopag Olamine Tablets?

The recommended initial dose is 7.5 mg once daily.

Download PDF (978 KB)